Journal Club

Recent Therapeutic Developments in RSV

 

brought to you by

Click on the link at left to go to your desired page:  Introduction  Page 2  Page 3  Study 1  Study 2  Study 3  Study 4  Conclusion  Implications for Social Workers  Post-Test 

Instructions

Take Another Course

Post-Test

Resources

Clinical management for RSV bronchiolitis and pneumonia is similar. Approximately 1% of all patients with RSV will require hospitalization. Admission is based on historical presentation, clinical findings, or laboratory and radiology results.1 Infants younger than 3 months or with less than 34 weeks gestation, or children with chronic lung or cardiac disease usually are admitted to the hospital depending on their respiratory status. Clinically, infants or children with respiratory rates higher than 70, wheezing and respiratory distress, a toxic and lethargic appearance, an oxygen saturation lower than 95% on room air, atelectasis or consolidation on chest radiograph, and hypercarbia warrant admission. Previously healthy patients generally are discharged within 24 to 72 hours, although infants and children with long-term heart and lung disease often have long and complicated hospital stays secondary to their inability to compensate for the alteration in ventilation28.

 

The primary treatment approach for any RSV infection is supportive, consisting of continuous monitoring, intravenous hydration, and administration of oxygen to correct hypoxemia. Areas of management on which there is varied agreement include the use of bronchodilators, antiviral therapy, corticosteroids, immunoprophylaxis, and routine testing for RSV antigens in infants hospitalized for RSV bronchiolitis.1 Pharmacologic treatments continue to be used, although there is limited evidence of their effectiveness.2–6 The treatment remains primarily supportive and aimed at symptom reduction. An effective treatment protocol must reduce obstructive respiratory symptoms, prevent recurrent symptoms, and be safe and cost effective.

Bronchodialators and corticosteroids  and Ribavirin may be effective in improving clinical symptoms, however they are associated with an annual cost of more than $37 million in the United States. 

Acute bronchiolitis early in life is associated with subsequent wheezing as the child grows. Described as a significant risk factor for asthma and wheezing,31 RSV increases cholinergic stimulation of the smooth muscle in the airway and the inflammatory response, mediated by a neuropeptide.1,32 The monoclonal antibody developed for use against the RSV protein, palivizumab, given either before or within 3 days of infection, has inhibited the inflammation in rats.33 This method may hold promise for the prevention of RSV infections.

 

References:
  1. Panitch HB. Bronchiolitis in infants. Curr Opin Pediatr . 2001;13(3):256–260.  
  1. McBride JT, McConnochie KM. RSV, recurrent wheezing, and ribaviran. Pediatr Pulmonol . 1998;25(3):145–146.  
  1. Kellner JD, Ohlssojn A, Gadomski AM, Wang EE. Bronchodilators for bronchitis. Cochrane Database Syst Rev. 2000;2:CD001266.  
  1. Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med . 2001; 344(25):1917–1928.  
  1. Van Woensel JB, Kimpen JL, Sprikkelman AB, Ouwehand A, van Aalderen WM. Long-term effects of prednisolone in the acute phase of bronchiolitis caused by respiratory syncytial virus. Pediatr Pulmonol . 2000;30(2):92–96.  
  1. Prince GA. An update on respiratory syncytial virus antiviral agents. Expert Opin Invest Drugs . 2001;10(2):297–308.  
  1. Hegele RG, Ahmad HY, Becker AB, et al. The association between respiratory viruses and symptoms in 2-week-old infants at high risk for asthma and allergy. J Pediatr . 2001;138:831–837.  
  1. Weber MW, Mulholland EK, Greenwood BM. Respiratory syncytial virus infection in tropical and developing countries. Trop Med Int Health . 1998;3:268–280.  
  1. Halstead DC, Jenkind SG. Continuous nonseasonal epidemic of respiratory syncytial virus infection in the southeast United States. South Med . 1998;91:433–436.  
  1. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost effectiveness in health and medicine. JAMA . 1996;104:419–442.  
  1. Schimdt AC, Couch RB, Galasso GJ, et al. Current research on respiratory viral infections: third international symposium. Antiviral Res . 2001;50(3):157–196.  
  1. Hall C, McBride J. Bronchiolitis. In: Mandell GL, ed. Principles and Practice of Infectious Diseases. New York: Churchill Livingstone; 1999.  
  1. Heilman C. National Institute of Allergy and Infectious Diseases and the World Health Organization. Respiratory syncytial and parainfluenza viruses. J Infect Dis . 1990;161:402–406.  
  1. Krilov LR. Respiratory syncytial virus: update on infection, treatment, and prevention. Curr Infect Dis Rep . 2001;3(3):242–246.  
  1. Nachman SA, Navaie-Waliser M, Quereshi MZ. Rehospitalization with respiratory syncytial virus after neonatal intensive care unit discharge: a 3-year follow-up. Pediatrics . 1997;100(6):E8.  
  1. Shay DK, Holman RC, Newman RD. Bronchiolitis-associated hospitalizations among US children, 1980–1996. JAMA . 1999;282:1440–1446.  
  1. Hall CB. Respiratory syncytial virus: a continuing culprit and conundrum. J Pediatr . 1999; 135:2–7.  
  1. Walsh EE, McConnochie KM, Long CE. Severity of respiratory syncytial virus infection is related to virus strain. J Infect Dis . 1997;175:814–820.  
  1. Ball TM, Castro-Rodriguez JA, Griffith KA, Holberg CJ, Martinez FD, Wright AL. Siblings, day care attendance and the risk of asthma and wheezing in childhood. N Engl J Med . 2000;343(8):638–643.  
  1. Welliver RC. Chemokines and cytokines in virus-induced wheezing. Presented at: Collaborative Investigators Symposium, American Academy of Allergy, Asthma, and Immunology Annual Meeting; March 3, 1999; Orlando, Fla.  
  1. Riejonen TM, Korppi M, Kuikka L. Serum eosinophil cationic protein as a predictor of wheezing after bronchiolitis. Pediatr Pulmonol . 1997;23:397–402.  
  1. Oymar K, Bjerknes R. Is serum eosinophil cationic protein in bronchiolitis a predictor of asthma? Pediatr Allergy Immunol . 1998;9:204–207. 
  1. Carabulli CM, Jafri HS, Yusuf M, Hatfield J, Ramilo O. Virologic and inflammatory markers in children with respiratory syncytial virus (RSV) lower respiratory tract infection: comparisons between outpatients and intubated infants. Acad Emerg Med . 2000;8(5):417–418.  
  1. Ehlenfield DR, Cameron K, Welliver RC. Eosinophilia at the time of respiratory syncytial virus bronchiolitis predicts childhood reactive airway disease. Pediatrics . 2000;105:79–83.  
  1. Hall CB. Respiratory syncytial virus. In: Feigin RD, Cherry JD, eds. Textbook of Pediatric Infectious Diseases. 4th ed. Philadelphia, Pa: WB Saunders; 1998.  
  1. Hall CB. Pathophysiology and pathogenicity. In: Weisman LE, Groothuis JR, eds. Contemporary Diagnosis and Management of Respiratory Syncytial Virus. Newton, Pa: Handbooks in Healthcare; 2000.  
  1. Rodriguez WJ. Therapy of RSV. In: Weisman LE, Groothuis JR, eds. Contemporary Diagnosis and Management of Respiratory Syncytial Virus. Newton, Pa: Handbooks in Healthcare.  
  1. Baker KA, Ryan ME. RSV infection in infants and young children. Postgrad Med . 1999; 106(7):97–111.  
  1. van Woensel JB, Kimpen J. Therapy for respiratory tract infections caused by respiratory syncytial virus. Eur J Pediatr . 2000;159(6):391–398.  
  1. Hesselmar B, Adolfson S. Inhalation of corticosteroids after hospital care for respiratory syncytial virus infection diminishes development of asthma in infants. Acta Paediatr . 2002;90(3):260–263.   Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B. Respiratory syncytial bronchiolitis in infancy is an important risk factor for asthma and allergy. Am J Respir Crit Care Med . 2000;161:1501–1507.  
  1. Thomas M, Bedford-Russell A, Sharland M. Prevention of respiratory syncytila virus infection with palivizumab. Mon Arch Chest Dis . 2000;55:333–338.  
  1. Driver LC, Oertel MD. palivizumab (Synagis): an anti-RSV monoclonal antibody. Pediatr Nurs . 1999; 5(5):527–530.  
  1. Rodriquez WJ. Management strategies for respiratory syncytial virus infections in infants. J Pediatr. 1999;Aug (supp):S46–S50.  
  1. American Academy of Pediatrics, Committee on Infectious Diseases. Respiratory syncytial virus. In: Peter G, ed. 1997 Red Book: Report of the Committee on Infectious Diseases. 24th ed. Elk Grove Village, Ill: American Academy of Pediatrics; 1997:446.  
  1. Guerguerian A, Gauther M, Lebl MH, Ferrell CA, Lacroix J. Ribavarin in ventilated respiratory syncytial virus bronchiolitis: a randomized, placebo-controlled trial. Am J Respir Crit Care Med . 1999;160:829–834.  
  1. Van Woensel JB, von Rosenstiel IA, Kimpen JL, Spanjaard L, van Aalderen WM. Antibiotic use in pediatric intensive care patients with lower respiratory tract infection due to respiratory syncytial virus. Intensive Care Med . 2001;27(8):1436.  
  1. van Woensel JB, Kimpen JL, Brand PL. Respiratory tract infections caused by respiratory syncytial virus in children: diagnosis and treatment. Minerva Pediatr . 2001;53(2):99–106.  
  1. Goldman DA. Epidemiology and prevention of pediatric viral respiratory infections in healthcare institutions. Emerg Infect Dis . 2001; 7(2):249–253.  
  1. Bergland V. Studies on respiratory syncytial virus infection. Acta Paediatr Scand . 1967; 176:1–40.  
  1. Gardner PS. Respiratory syncytial virus infections. Postgrad Med J . 1973;49:788–791.  
  1. Hall CB. Pathology and pathogenicity. In Weisman LE, Groothius JR, eds. Contemporary Diagnosis and Management of Respiratory Syncytial Virus. Newtown, Pa: Handbooks in Healthcare Co.; 2000.  
  1. Tyrell DA. Discovering and defining the etiology of acute respiratory disease. Am Rev Respir Dis . 1988;88:77–84.  
  1. Reilly CM, Stokes J, McClelland L. Studies of acute respiratory illness caused by respiratory syncytial virus. N Engl J Med . 1961;264:1176–1182.
  2. MacCartney KK, Gorelick MH, Manning ML. Nosocomial respiratory syncytial virus infections: the cost effectiveness and cost-benefit of infection control. Pediatrics . 2000;106:520–526.

 

Click on the link at left to go to your desired page:  Introduction  Page 2  Page 3  Study 1  Study 2  Study 3  Study 4  Conclusion  Implications for Social Workers  Post-Test 

Continue on to Study 1

2002 Hi-R-Ed Online University. All courses posted on this site are the property of Hi-R-Ed Online University unless otherwise stated. Courses may not be copied or transferred in electronic, printed, or other forms, or modified for any purpose without explicit written consent of Hi-R-Ed Online University.